
News from Pharmaceutical Business review
Top Pharmaceutical Business Review News

United States · United StatesOn Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002. Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). “We look …See the Story
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma (NASDAQ:AMPH), Fresenius Medical Care (NYSE:FMS)
Coverage: 2 sources